Table 1.
Baseline characteristics of patients with COVID‐19 in SIM01 and control arms
| SIM01 (n = 25) | Controls (n = 30) | P value | |
|---|---|---|---|
| Male, n (%) | 14 (56) | 9 (30) | 0.052 |
| Median age, years (IQR) | 50 (39–59) | 46.5 (29.5–56) | 0.151 |
| Smokers/ex‐smokers, n (%) | 7 (28) | 6 (20) | 0.298 |
| Drinkers/ex‐drinkers, n (%) | 2 (8) | 1 (3) | 0.585 |
| Comorbidities, n (%) | 11 (44) | 16 (53) | 0.729 |
| Recent exposure history, n (%) | |||
| Travel history | 0 (0) | 2 (6.7) | 1.000 |
| Contact with person with COVID‐19 | 18 (72) | 19 (63) | 0.448 |
| Symptoms at admission, n (%) | |||
| Fever | 20 (80) | 15 (50) | 0.030 |
| Ageusia/anosmia | 4 (16) | 4 (13) | |
| Myalgia | 5 (20) | 1 (3) | 0.085 |
| Malaise | 3 (12) | 7 (23) | 0.309 |
| Gastrointestinal symptoms | |||
| Diarrhea | 6 (24) | 5 (17) | 0.736 |
| Respiratory symptoms | |||
| Cough | 15 (60) | 16 (53) | 0.721 |
| Sputum | 3 (12) | 8 (27) | 0.156 |
| Sore throat | 7 (28) | 11 (37) | 0.440 |
| Rhinorrhea | 4 (16) | 5 (17) | 1.000 |
| Shortness of breath | 4 (16) | 3 (10) | 0.692 |
| Medications for COVID‐19, n (%) | |||
| Antibiotic | 4 (16) | 6 (20) | 0.741 |
| Antiviral drug | 12 (48) | 19 (63) | 0.254 |
| Dexamethasone | 4 (16) | 5 (17) | 1.000 |
| Pneumonia changes on chest X‐ray at admission, n (%) | 10 (40) | 13 (43) | 1.000 |
| Disease severity on admission, n (%) | |||
| Mild | 16 (64) | 21 (70) | 0.637 |
| Moderate | 8 (32) | 8 (27) | 0.665 |
| Severe | 1 (4) | 1 (3) | 1.000 |
| Critical | 0 (0) | 0 (0) | N/A |
IQR, interquartile range.